Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium hydroxide added to tamsulosin for urinary symptoms in benign prostatic hyperplasia
IRCT20180115038379N1Phase 3Completed
- Sponsor
- Shahroud University of Medical Sciences
- Start
- Aug 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Magnesium hydroxide in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Shahroud University of Medical Sciences. Primary endpoints: Feeling of bladder emptying, Repeat urination within 2 hours and 3 more. Started Aug 2017; status: completed.
02
Drugs
Magnesium hydroxide
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20180115038379N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180115038379N1.